Vildagliptin add-on to Glimepiride Versus Placebo Added to Glimepiride in Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 279 participants.

Also called NCT01357252

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 279 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01357252
Other papers using this trial's data
  • Vildagliptin added to sulfonylurea improves glycemic control without hypoglycemia and weight gain in Chinese patients with type 2 diabetes mellitus Journal of diabetes, 2015-03 DOI, PubMed 24823599

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01357252. Randomized; triple masking; primary purpose treatment. Start 2011-04 (registry gives no type); primary completion 2013-01 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Vildagliptin add-on to Glimepiride Versus Placebo Added to Glimepiride in Type 2 Diabetes
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
vildagliptin
Intervention (Drug)
Placebo
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct01357252
Content hash
4baf7b33a5cdda446f9b1980c5a1fd0b888c7de38651809a6890c93c1dc1f068